Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SPRO

Spero Therapeutics Inc

Last Close
Sep 06 • 04:00PM ET
1.32
Dollar change
-0.01
Percentage change
-1.13 		%
Held by: VTI VXF IWC Scroll to Statements
Index- P/E3.92 EPS (ttm)0.34 Insider Own28.13% Shs Outstand53.00M Perf Week-4.01%
Market Cap71.08M Forward P/E- EPS next Y-1.33 Insider Trans-0.28% Shs Float38.84M Perf Month6.91%
Income17.46M PEG0.11 EPS next Q-0.50 Inst Own22.14% Short Float0.97% Perf Quarter-9.31%
Sales105.43M P/S0.67 EPS this Y-409.88% Inst Trans-5.11% Short Ratio2.80 Perf Half Y-23.99%
Book/sh1.49 P/B0.88 EPS next Y0.19% ROA14.03% Short Interest0.38M Perf Year-4.71%
Cash/sh1.18 P/C1.12 EPS next 5Y36.90% ROE25.81% 52W Range0.99 - 1.89 Perf YTD-10.54%
Dividend Est.- P/FCF- EPS past 5Y- ROI20.85% 52W High-30.42% Beta0.63
Dividend TTM- Quick Ratio2.68 Sales past 5Y586.08% Gross Margin99.13% 52W Low32.83% ATR (14)0.07
Dividend Ex-Date- Current Ratio2.68 EPS Y/Y TTM232.31% Oper. Margin7.43% RSI (14)47.38 Volatility3.97% 5.58%
Employees46 Debt/Eq0.06 Sales Y/Y TTM115.32% Profit Margin16.56% Recom1.00 Target Price7.50
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q-46.07% Payout0.00% Rel Volume0.95 Prev Close1.33
Sales Surprise108.10% EPS Surprise13.16% Sales Q/Q663.58% EarningsAug 05 AMC Avg Volume134.61K Price1.32
SMA200.57% SMA50-2.12% SMA200-9.61% Trades Volume128,470 Change-1.13%
Date Action Analyst Rating Change Price Target Change
Sep-23-22Upgrade Evercore ISI In-line → Outperform $2 → $8
Oct-01-21Downgrade Oppenheimer Outperform → Perform
Jan-22-21Reiterated H.C. Wainwright Buy $33 → $40
Dec-16-20Initiated Berenberg Buy $47
Sep-29-20Initiated Evercore ISI Outperform
Nov-05-19Reiterated H.C. Wainwright Buy $28 → $35
Sep-09-19Initiated Janney Buy
Feb-09-18Initiated Cantor Fitzgerald Overweight $27
Nov-27-17Initiated Stifel Buy $26
Nov-27-17Initiated Oppenheimer Outperform $30
Show Previous Ratings
Sep-04-24 04:05PM
Spero Therapeutics to Present at Upcoming September Investor Conferences
(GlobeNewswire)
Aug-06-24 07:51AM
Q2 2024 Spero Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) -5.22%
Aug-05-24 08:59PM
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
(InvestorPlace)
05:35PM
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
04:01PM
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
(GlobeNewswire)
04:05PM Loading…
Jul-29-24 04:05PM
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
(GlobeNewswire)
Jul-08-24 03:07PM
3 Micro-Cap Moonshots for Fearless Investors
(InvestorPlace)
Jul-03-24 01:05PM
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-03-24 04:05PM
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
May-16-24 04:05PM
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
(GlobeNewswire)
May-15-24 08:55PM
SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024
(InvestorPlace)
04:05PM
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
(GlobeNewswire)
May-08-24 08:00AM
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
(GlobeNewswire)
May-01-24 04:07PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +8.80%
Apr-16-24 11:52AM
14 Cheap Penny Stocks to Buy According to Analysts
(Insider Monkey)
12:51PM Loading…
Mar-15-24 12:51PM
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Mar-14-24 06:33AM
Q4 2023 Spero Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-13-24 05:10PM
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
(Zacks)
04:01PM
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
(GlobeNewswire)
Mar-06-24 08:05AM
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
(GlobeNewswire)
Feb-28-24 08:05AM
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
(GlobeNewswire)
Feb-26-24 08:05AM
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
(GlobeNewswire)
Feb-05-24 11:27PM
Spero Therapeutics Inc CEO Sath Shukla Sells 75,994 Shares
(GuruFocus.com)
Jan-31-24 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-29-24 04:07AM
15 Cash-Rich Penny Stocks Hedge Funds Are Buying
(Insider Monkey)
Jan-25-24 04:40AM
11 Hyper-Growth Stocks Billionaires Are Loading Up On
(Insider Monkey)
Jan-05-24 08:05AM
Spero Therapeutics Provides Corporate Update and 2024 Outlook
(GlobeNewswire)
Jan-02-24 08:05AM
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
(GlobeNewswire)
Nov-14-23 09:02AM
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-13-23 04:05PM
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
(GlobeNewswire)
08:05AM Loading…
Nov-06-23 08:05AM
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
(GlobeNewswire)
Nov-01-23 04:05PM
Spero Therapeutics to Present at Upcoming November Investor Conferences
(GlobeNewswire) +5.56%
08:05AM
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
(GlobeNewswire)
Oct-31-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-18-23 12:00PM
All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy
(Zacks)
Sep-29-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-20-23 04:05PM
Spero Therapeutics to Present at Cantors Global Healthcare 2023 Investor Conference
(GlobeNewswire)
Sep-16-23 01:01PM
Insider Sell: Chief Medical Officer Kamal Hamed Sells 39,496 Shares of Spero Therapeutics Inc
(GuruFocus.com)
Sep-12-23 08:00AM
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
(GlobeNewswire)
Sep-06-23 08:05AM
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-31-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Aug-29-23 12:00PM
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?
(Zacks) +8.73%
Aug-22-23 05:45PM
Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
(Zacks)
Aug-13-23 05:24AM
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript
(Insider Monkey)
Aug-11-23 06:32AM
Q2 2023 Spero Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Aug-10-23 06:05PM
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
04:05PM
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update
(GlobeNewswire)
Aug-03-23 08:05AM
Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
(GlobeNewswire)
Jul-31-23 08:05AM
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
(GlobeNewswire) +14.79%
Jul-05-23 06:20AM
Investors in Spero Therapeutics (NASDAQ:SPRO) have unfortunately lost 90% over the last three years
(Simply Wall St.)
Jun-30-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-18-23 07:51PM
Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?
(Zacks)
Jun-14-23 08:05AM
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer
(GlobeNewswire) -5.81%
May-31-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
May-18-23 07:09AM
Time To Worry? Analysts Are Downgrading Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Outlook
(Simply Wall St.)
May-16-23 11:36AM
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2023 Earnings Call Transcript
(Insider Monkey)
May-12-23 05:30AM
Q1 2023 Spero Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
May-11-23 05:35PM
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
04:05PM
Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update
(GlobeNewswire)
May-04-23 08:05AM
Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
(GlobeNewswire)
Apr-28-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-26-23 08:05AM
Spero Therapeutics to Present at Upcoming Investor Conference
(GlobeNewswire)
Apr-17-23 07:14AM
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
(Simply Wall St.)
Apr-14-23 08:05AM
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
(GlobeNewswire)
Apr-13-23 06:19AM
Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
(Simply Wall St.) +5.56%
Apr-05-23 09:59PM
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2022 Earnings Call Transcript
(Insider Monkey) -5.84%
Apr-01-23 09:07AM
Spero Therapeutics (NASDAQ:SPRO) Is In A Strong Position To Grow Its Business
(Simply Wall St.)
Mar-31-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-30-23 06:05PM
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates
(Zacks)
04:05PM
Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update
(GlobeNewswire)
Mar-13-23 08:05AM
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
(GlobeNewswire)
Mar-06-23 08:05AM
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023
(GlobeNewswire)
Feb-28-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
08:05AM
Spero Therapeutics to Present at Upcoming Investor Conferences
(GlobeNewswire)
Feb-23-23 09:35AM
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
(Zacks)
Feb-22-23 09:35AM
Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-31-23 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-14-23 08:03AM
Spero Therapeutics (NASDAQ:SPRO) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 85%
(Simply Wall St.)
Dec-22-22 04:05PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-22-22 08:05AM
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
(GlobeNewswire)
Nov-16-22 05:55AM
Spero Therapeutics Third Quarter 2022 Earnings: Misses Expectations
(Simply Wall St.)
Nov-14-22 05:25PM
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
(Zacks) -7.39%
04:05PM
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update
(GlobeNewswire)
Nov-08-22 08:05AM
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
(GlobeNewswire)
Nov-07-22 08:05AM
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
(GlobeNewswire)
Nov-02-22 10:01AM
Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?
(Zacks)
Oct-19-22 08:05AM
Spero Therapeutics to Present Data at IDWeek 2022
(GlobeNewswire) -11.27%
Oct-03-22 08:05AM
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
(GlobeNewswire)
Sep-25-22 07:00AM
This Infection-Fighting Biotech Is Recovering Nicely
(TheStreet.com)
Sep-23-22 11:02AM
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
(Zacks) -10.45%
Sep-22-22 11:30AM
GSK picks up troubled Spero drug for nearly $300M, takes stake in company
(American City Business Journals) +167.74%
10:53AM
Spero's stock jumps 188% after GSK licenses experimental antibiotic
(MarketWatch)
07:20AM
Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic
(Benzinga)
02:00AM
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
(GlobeNewswire)
Sep-15-22 04:05PM
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
(GlobeNewswire) -7.22%
Sep-07-22 12:37PM
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More
(Zacks) +26.55%
10:36AM
Spero (SPRO) Up Following Positive FDA Update for UTI Drug
(Zacks)
08:05AM
Spero Therapeutics to Present at Upcoming Investor Conference
(GlobeNewswire)
Sep-06-22 10:10AM
Spero Therapeutics Shares Jump After Upbeat FDA Feedback For Tebipenem HBr Program
(Benzinga) +55.50%
08:05AM
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
(GlobeNewswire)
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahadevia AnkitDirectorAug 27 '24Sale1.355,9127,981759,085Aug 29 06:43 PM
Keutzer TimothyChief Operating OfficerAug 27 '24Sale1.352,2132,988531,837Aug 29 06:42 PM
Shukla SathCEO & PresidentAug 27 '24Sale1.352,7573,7221,140,809Aug 29 06:36 PM
Shukla SathCEO and PresidentAug 05 '24Sale1.3117,64123,1101,143,566Aug 06 07:56 PM
Shukla SathCEO and PresidentAug 02 '24Sale1.3214,80019,5361,161,207Aug 06 07:56 PM
Keutzer TimothyChief Operating OfficerFeb 02 '24Sale1.3630,97142,121534,050Feb 05 08:53 PM
Mahadevia AnkitDirectorFeb 02 '24Sale1.3763,79587,399744,997Feb 05 08:50 PM
JOSEPH TAMARA LChief Legal OfficerFeb 02 '24Sale1.3730,90642,341531,615Feb 05 08:48 PM
HAMED KAMALChief Medical OfficerFeb 02 '24Sale1.3728,07538,463788,117Feb 05 08:45 PM
Shukla SathCEO and PresidentFeb 05 '24Sale1.4545,09365,3851,176,007Feb 05 08:40 PM
Shukla SathCEO and PresidentFeb 02 '24Sale1.3730,90142,3341,221,100Feb 05 08:40 PM
HAMED KAMALChief Medical OfficerSep 13 '23Sale1.2739,49650,160576,461Sep 15 05:47 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.